Xencor (XNCR) is expected to report a Q3 2026 consensus revenue of $63.00 million and an EPS of -$0.34, with the stock currently trading around $24.77 compared to an average analyst target of $31.42.
Investors are primarily focused on clinical updates for the company's oncology pipeline, particularly the developmental progress of its ENPP3 x CD3 bispecific antibody, XmAb819, in advanced renal cell carcinoma.
The projected revenue represents a 200% year-over-year increase, driven by normalized royalty streams and milestone payments from partners like Incyte and Alexion.
Market participants are also assessing Xencor's cash runway, which is currently estimated to extend into mid-2028 following recent strategic shifts toward T-cell engagers.